Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
Octaplas is a human plasma protein solution administered intravenously, derived from pooled human plasma. It is indicated for patients requiring plasma transfusion, serving as a virally inactivated alternative to standard fresh frozen plasma. The product works by replacing deficient plasma proteins and clotting factors in patients with coagulation disorders or massive transfusion requirements.
At peak lifecycle, Octaplas likely has stable market presence with moderate commercial infrastructure, though specific team size data is unavailable.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Observational Study of the Use of octaplasLG®.
Octaplas Adult TTP Trial
Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation
Octaplas Pediatric Plasma Exchange Trial
Octaplas Pediatric Plasma Replacement Trial
Worked on Octaplas at Octapharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Octaplas positions you in a stable, mature product with established market dynamics, offering solid commercial and medical affairs experience in plasma-derived therapeutics. However, limited linked job postings suggest a smaller dedicated team and fewer active hiring initiatives compared to growth-stage products.